CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2017

Summary

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells. 

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 20 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 13 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Infectious Disease and Hematological Disorders which include indications Breast Cancer, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Graft Versus Host Disease (GVHD), Hepatitis B, Hepatocellular Carcinoma, Lymphoma, Metastatic Melanoma, B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus Infections, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus. 

The latest report CD40 Ligand - Pipeline Review, H2 2017, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects 
- The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview 7
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment 18
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
eTheRNA Immunotherapies NV 24
Juno Therapeutics Inc 25
MedImmune LLC 25
Memgen LLC 26
Multimeric Biotherapeutics Inc 26
Sanofi 26
Tessa Therapeutics Pte Ltd 27
TILT Biotherapeutics Ltd 27
UCB SA 27
XL-protein GmbH 28
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles 29
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dapirolizumab pegol - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Delta-24-RGDOX - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Dendritic Cell Therapy + TILT-234 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ECI-006 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
hepatitis B vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
INX-021 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ISF-35 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
letolizumab - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LOAd-700 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
MEDI-4920 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
MegaCD40L - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
NJA-730 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TDI-28 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
TDI-846 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
TT-16 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
UltraCD40L - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
XL-050 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products 54
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones 56
Featured News & Press Releases 56
Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016) 56
Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma 56
Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS 57
Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting 57
Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011 58
Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 58
Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia 59
Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy 60
Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting 60
Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting 60
Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia 61
Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia 61
Oct 21, 1999: Biogen Announces Halt In Several Trials Of Anti-CD40 Ligand Monoclonal Antibody 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Number of Products under Investigation by Universities/Institutes, H2 2017 16
Products under Investigation by Universities/Institutes, H2 2017 17
Number of Products by Stage and Mechanism of Actions, H2 2017 19
Number of Products by Stage and Route of Administration, H2 2017 21
Number of Products by Stage and Molecule Type, H2 2017 23
Pipeline by Bristol-Myers Squibb Company, H2 2017 24
Pipeline by eTheRNA Immunotherapies NV, H2 2017 25
Pipeline by Juno Therapeutics Inc, H2 2017 25
Pipeline by MedImmune LLC, H2 2017 26
Pipeline by Memgen LLC, H2 2017 26
Pipeline by Multimeric Biotherapeutics Inc, H2 2017 26
Pipeline by Sanofi, H2 2017 27
Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 27
Pipeline by TILT Biotherapeutics Ltd, H2 2017 27
Pipeline by UCB SA, H2 2017 28
Pipeline by XL-protein GmbH, H2 2017 28
Dormant Products, H2 2017 54
Dormant Products, H2 2017 (Contd..1), H2 2017 55